News
BerGenBio ASA: Board approval of 2024 Annual financial statement and Annual Report 2024 and update on financial calendar
BerGenBio announces Nature Communications Publication of BGBC003 Ph2 data in relapsed/refractory Acute Myeloid Leukemia patients
BerGenBio announces advancement of its strategic review
BerGenBio Fourth Quarter Results 2024
BerGenBio announces discontinuation of 1L STK11M NSCLC study and exploration of strategic alternatives
BerGenBio ASA: Invitation to fourth quarter 2024 results webcast
BerGenBio Announces First Patient Entered Into Advanced Adenocarcinoma Lung Cancer Trial
BerGenBio to Present Company Update at DNB Nordic Healthcare Conference
BerGenBio Appoints Olav Hellebø as CEO